{"Title": ["MYOV To Report SPIRIT 1 Data, EVLO Joins COVID-19 Drug Race, NVTA Loosens Purse Strings", "BUZZ-U.S. STOCKS ON THE MOVE-Nike, TripAdvisor, U.S. Cruise Operators", "ADCT Closes IPO, ALDX To Provide COVID-19 Update, RWLK To Focus On Telehealth", "FDA Delays Decision On HRTX Drug, KPTI On Watch, ADMP To Resubmit NDA In Q2", "BBI Awaits Data In Q2, BLPH Breathes Easy, Big Day For BXRX Tomorrow", "Health Care Sector Update for 12/27/2019: FLXN, FPRX, SPPI, JNJ, PFE, ABT, MRK, AMGN", "LPCN Awaits FDA Word, NKTR On Track, All's Well With Five Prime's FPT155", "MITO Empowered, FPRX Cuts Another 70 Jobs, Second Death In Legionnaires Outbreak", "MYOV To Report SPIRIT 1 Data, EVLO Joins COVID-19 Drug Race, NVTA Loosens Purse Strings", "BUZZ-U.S. STOCKS ON THE MOVE-Nike, TripAdvisor, U.S. Cruise Operators", "ADCT Closes IPO, ALDX To Provide COVID-19 Update, RWLK To Focus On Telehealth", "FDA Delays Decision On HRTX Drug, KPTI On Watch, ADMP To Resubmit NDA In Q2", "BBI Awaits Data In Q2, BLPH Breathes Easy, Big Day For BXRX Tomorrow", "Health Care Sector Update for 12/27/2019: FLXN, FPRX, SPPI, JNJ, PFE, ABT, MRK, AMGN", "MacroGenics Up on Lifting of Partial Hold on Cancer Candidate", "Five Prime Therapeutics, Inc. (FPRX) Shares March Higher, Can It Continue?", "5 Top Gainers In Healthcare Sector (OCGN, CATB, SOLY\u2026)", "Health Care Sector Update for 10/09/2019: FPRX,OCGN,DERM,DBVT", "Peek Under The Hood: VHT Has 17% Upside", "3 Top Chinese Stocks to Watch in May", "Will Five Prime Therapeutics Continue to Surge Higher?", "Five Prime Therapeutics Inc (FPRX) Q4 2018 Earnings Conference Call Transcript", "MacroGenics Up on Lifting of Partial Hold on Cancer Candidate", "Five Prime Therapeutics, Inc. (FPRX) Shares March Higher, Can It Continue?", "5 Top Gainers In Healthcare Sector (OCGN, CATB, SOLY\u2026)", "Five Prime Therapeutics (FPRX) Reports Q3 Loss, Misses Revenue Estimates", "Nobel Prize for Cancer Immunotherapy & Biotech ETFs to Buy", "Commit To Buy Five Prime Therapeutics At $10, Earn 19.6% Annualized Using Options", "Five Prime Therapeutics (FPRX) Reports Q2 Loss, Tops Revenue Estimates", "Five Prime Therapeutics Sees Hammer Chart Pattern: Time to Buy?", "5 Top-Ranked High-Beta Stocks to Play the Roaring Market", "5 Top-Ranked High-Beta Stocks to Play the Roaring Market", "3 Top Biotech Stocks to Buy Right Now", "5 Stocks that Boast Superb Earnings Acceleration", "Why This Biotech Could Prosper On Back Of Roche Cancer Trial", "Why This Biotech Still Gets Hit Despite Promising Cancer Data", "Why Five Prime Therapeutics Stock Is on the Rebound Today", "Health Care Sector Update for 11/07/2017: SELB,MYO,FPRX,BMY", "Noteworthy Tuesday Option Activity: HLF, MNK, FPRX", "Health Care Sector Update for 11/07/2017: TLGT,MYO,FPRX,BMY", "Stocks Showing Improving Market Leadership: Five Prime Therapeutics Earns 83 RS Rating", "Five Prime Therapeutics, Inc. (FPRX) Jumps: Stock Rises 6.2%", "Noteworthy Friday Option Activity: FPRX, LULU, GOOGL", "Five Prime Therapeutics Becomes Oversold (FPRX)", "Commit To Buy Five Prime Therapeutics At $35, Earn 9.7% Annualized Using Options", "Bristol-Myers Extends Deal with Five Prime Therapeutics", "Commit To Buy Five Prime Therapeutics At $40, Earn 13.4% Annualized Using Options", "Stock Picks for Quant Strategies", "Stocks Showing Improving Market Leadership: Five Prime Therapeutics Earns 83 RS Rating", "Commit To Purchase Five Prime Therapeutics At $35, Earn 9.7% Annualized Using Options", "FPRX Crosses Above Average Analyst Target", "Commit To Purchase Five Prime Therapeutics At $40, Earn 22.8% Annualized Using Options", "Noteworthy ETF Inflows: XBI, FPRX, DYAX, ACHN", "Notable ETF Outflow Detected - XBI, FPRX, DYAX, ZIOP", "Why Five Prime Therapeutics Rocketed 109% Higher in October", "XBI, FPRX, DYAX, JUNO: ETF Outflow Alert", "After-Hours Earnings Report for March 10, 2016 : ULTA, FNV, PAY, HTHT, FNSR, VNET, FPRX, MMI, IRET, PRSC, FTD, FF", "Bristol-Myers' (BMY) Daklinza Gets NICE Recommendation", "Pre-Market Most Active for Oct 15, 2015 : NOK, C, NFLX, STX, VRX, BAC, MTW, FPRX, ALU, TVIX, TTHI, XIV", "Five Prime Therapeutics and Bristol-Myers Squibb Co. Deepen Their Ties", "Five Prime Therapeutics Stock Soars Over 60% On News of Deal With Bristol-Myers Squibb", "Moving Average Crossover Alert: Five Prime Therapeutics (FPRX)", "3 Top Small-Cap Biotech Stocks to Buy Right Now", "Should You Get Rid of Five Prime Therapeutics (FPRX) Now?", "The Lazy Way to Invest in Cancer Immunotherapy", "Use Options For a Chance To Buy FPRX at a 20% Discount", "Five Prime Therapeutics (FPRX) Jumps: Stock Rises 15.1% - Tale of the Tape", "After-Hours Earnings Report for May 13, 2015 : CSCO, NTES, VIPS, CTRP, MIDD, JACK, WX, JCP, CIB, LXFT, FPRX, RVNC", "Is Immuno-Oncology the Best Area of Biotech to Invest in Right Now?", "Weakness Seen in Five Prime Therapeutics (FPRX) Estimates: Should You Stay Away? - Tale of the Tape", "After-Hours Earnings Report for March 17, 2015 : ORCL, ADBE, NVGS, FPRX, CPXX, AEZS, BONE, BCYP", "Steven Cohen's Newest Buys, Additions and Reductions", "The Zacks Analyst Blog Highlights: Amgen, Exelixis, Regeneron, Five Prime Therapeutics and AbbVie - Press Releases", "5 Things Bristol-Myers Squibb Co.'s Management Wants You to Know", "Steven Cohen Buys Stake in Company Looking For Buyer", "Tuesday 1/20 Insider Buying Report: JPM, FPRX", "Could This Common Medicine Cabinet Supplement Be the Key to Increased Survival for Some Cancer Patie", "3 Clinical Stage Biotech Stocks That Should Be on Your Watchlist in 2015", "MacroGenics Inks Deal with J&J for Blood Cancer Therapy - Analyst Blog", "Five Prime Therapeutics Up on Deal with Bristol-Myers - Analyst Blog", "Has Pfizer Inc. Finally Solved Its Immuno-oncology Problem?", "Monday Sector Leaders: Music & Electronics Stores, Drugs", "Five Prime Therapeutics' Novel Target Licensed by Glaxo - Analyst Blog", "Five Prime Therapeutics (FPRX) Jumps: Stock Adds 10.3% in Session - Tale of the Tape", "Bristol-Myers & CytomX Therapeutics Join Forces - Analyst Blog", "Bristol-Myers, Samsung BioLogics Extend Ties - Analyst Blog", "Should Five Prime Therapeutics (FPRX) Be On Your Radar Now? - Tale of the Tape", "Earnings Estimates Moving Higher for Five Prime (FPRX): Time to Buy? - Tale of the Tape", "Five Prime Therapeutics, Inc. (FPRX) in Focus: Stock Soars 31.4% - Tale of the Tape", "Monday Sector Leaders: Music & Electronics Stores, Drugs", "Five Prime Therapeutics' Novel Target Licensed by Glaxo - Analyst Blog", "Five Prime Therapeutics prices IPO at $13, within the range", "US IPO Recap: Benefitfocus, six others set terms as calendar rebuilds", "Biotech Five Prime Therapeutics sets terms for $52 million IPO", "Bristol Myers Deal Overshadows Q4 loss at Five Prime - Analyst Blog"], "Elapsed Time": ["5 DAYS AGO", "5 DAYS AGO", "MAY 19, 2020", "FEB 19, 2020", "FEB 19, 2020", "DEC 27, 2019", "NOV 10, 2019", "OCT 11, 2019", "5 DAYS AGO", "5 DAYS AGO", "MAY 19, 2020", "FEB 19, 2020", "FEB 19, 2020", "FEB 26, 2019", "JAN 28, 2019", "JAN 24, 2019", "OCT 9, 2019", "OCT 9, 2019", "AUG 8, 2019", "MAY 1, 2019", "MAR 19, 2019", "FEB 26, 2019", "JAN 28, 2019", "JAN 24, 2019", "OCT 9, 2019", "NOV 6, 2018", "OCT 8, 2018", "SEP 28, 2018", "AUG 8, 2018", "JUN 21, 2018", "JUN 7, 2018", "JUN 7, 2018", "NOV 27, 2018", "MAR 22, 2018", "NOV 22, 2017", "NOV 13, 2017", "NOV 8, 2017", "NOV 7, 2017", "NOV 7, 2017", "NOV 7, 2017", "OCT 16, 2017", "OCT 13, 2017", "AUG 18, 2017", "MAR 17, 2017", "FEB 1, 2017", "JAN 5, 2017", "NOV 1, 2016", "OCT 4, 2016", "OCT 16, 2017", "AUG 2, 2016", "JUL 19, 2016", "DEC 15, 2015", "NOV 24, 2015", "NOV 16, 2015", "NOV 14, 2015", "NOV 6, 2015", "MAR 10, 2016", "OCT 16, 2015", "OCT 15, 2015", "OCT 15, 2015", "OCT 15, 2015", "SEP 2, 2015", "AUG 24, 2015", "AUG 13, 2015", "OCT 16, 2015", "JUN 25, 2015", "MAY 28, 2015", "MAY 13, 2015", "APR 22, 2015", "MAR 25, 2015", "MAR 17, 2015", "MAR 4, 2015", "JUL 23, 2015", "FEB 4, 2015", "JAN 29, 2015", "JAN 20, 2015", "JAN 18, 2015", "DEC 23, 2014", "DEC 23, 2014", "NOV 26, 2014", "FEB 18, 2015", "NOV 24, 2014", "SEP 17, 2014", "AUG 12, 2014", "MAY 28, 2014", "APR 23, 2014", "APR 10, 2014", "APR 4, 2014", "NOV 25, 2014", "NOV 24, 2014", "SEP 17, 2014", "SEP 17, 2013", "SEP 8, 2013", "SEP 4, 2013", "MAR 27, 2014"], "Published Date": [], "Link": ["https://www.nasdaq.com/articles/myov-to-report-spirit-1-data-evlo-joins-covid-19-drug-race-nvta-loosens-purse-strings-2020", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-nike-tripadvisor-u.s.-cruise-operators-2020-06-22", "https://www.nasdaq.com/articles/adct-closes-ipo-aldx-to-provide-covid-19-update-rwlk-to-focus-on-telehealth-2020-05-19", "https://www.nasdaq.com/articles/fda-delays-decision-on-hrtx-drug-kpti-on-watch-admp-to-resubmit-nda-in-q2-2020-02-19", "https://www.nasdaq.com/articles/bbi-awaits-data-in-q2-blph-breathes-easy-big-day-for-bxrx-tomorrow-2020-02-19", "https://www.nasdaq.com/articles/health-care-sector-update-for-12-27-2019%3A-flxn-fprx-sppi-jnj-pfe-abt-mrk-amgn-2019-12-27", "https://www.nasdaq.com/articles/lpcn-awaits-fda-word-nktr-on-track-alls-well-with-five-primes-fpt155-2019-11-10", "https://www.nasdaq.com/articles/mito-empowered-fprx-cuts-another-70-jobs-second-death-in-legionnaires-outbreak-2019-10-11", "https://www.nasdaq.com/articles/myov-to-report-spirit-1-data-evlo-joins-covid-19-drug-race-nvta-loosens-purse-strings-2020", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-nike-tripadvisor-u.s.-cruise-operators-2020-06-22", "https://www.nasdaq.com/articles/adct-closes-ipo-aldx-to-provide-covid-19-update-rwlk-to-focus-on-telehealth-2020-05-19", "https://www.nasdaq.com/articles/fda-delays-decision-on-hrtx-drug-kpti-on-watch-admp-to-resubmit-nda-in-q2-2020-02-19", "https://www.nasdaq.com/articles/bbi-awaits-data-in-q2-blph-breathes-easy-big-day-for-bxrx-tomorrow-2020-02-19", "https://www.nasdaq.com/articles/five-prime-therapeutics-inc-fprx-q4-2018-earnings-conference-call-transcript-2019-02-26", "https://www.nasdaq.com/articles/macrogenics-up-on-lifting-of-partial-hold-on-cancer-candidate-2019-01-28", "https://www.nasdaq.com/articles/five-prime-therapeutics-inc.-fprx-shares-march-higher-can-it-continue-2019-01-24", "https://www.nasdaq.com/articles/5-top-gainers-in-healthcare-sector-ocgn-catb-soly...-2019-10-09", "https://www.nasdaq.com/articles/health-care-sector-update-for-10-09-2019%3A-fprxocgndermdbvt-2019-10-09", "https://www.nasdaq.com/articles/peek-under-the-hood%3A-vht-has-17-upside-2019-08-08", "https://www.nasdaq.com/articles/3-top-chinese-stocks-watch-may-2019-05-01", "https://www.nasdaq.com/articles/will-five-prime-therapeutics-continue-to-surge-higher-2019-03-19", "https://www.nasdaq.com/articles/five-prime-therapeutics-inc-fprx-q4-2018-earnings-conference-call-transcript-2019-02-26", "https://www.nasdaq.com/articles/macrogenics-up-on-lifting-of-partial-hold-on-cancer-candidate-2019-01-28", "https://www.nasdaq.com/articles/five-prime-therapeutics-inc.-fprx-shares-march-higher-can-it-continue-2019-01-24", "https://www.nasdaq.com/articles/5-top-gainers-in-healthcare-sector-ocgn-catb-soly...-2019-10-09", "https://www.nasdaq.com/articles/five-prime-therapeutics-fprx-reports-q3-loss-misses-revenue-estimates-2018-11-06", "https://www.nasdaq.com/articles/nobel-prize-cancer-immunotherapy-biotech-etfs-buy-2018-10-08", "https://www.nasdaq.com/articles/commit-buy-five-prime-therapeutics-10-earn-196-annualized-using-options-2018-09-28", "https://www.nasdaq.com/articles/five-prime-therapeutics-fprx-reports-q2-loss-tops-revenue-estimates-2018-08-08", "https://www.nasdaq.com/articles/five-prime-therapeutics-sees-hammer-chart-pattern%3A-time-to-buy-2018-06-21", "https://www.nasdaq.com/articles/5-top-ranked-high-beta-stocks-play-roaring-market-2018-06-07-0", "https://www.nasdaq.com/articles/5-top-ranked-high-beta-stocks-play-roaring-market-2018-06-07", "https://www.nasdaq.com/articles/3-top-biotech-stocks-buy-right-now-2018-11-27", "https://www.nasdaq.com/articles/5-stocks-boast-superb-earnings-acceleration-2018-03-22", "https://www.nasdaq.com/articles/why-biotech-could-prosper-back-roche-cancer-trial-2017-11-22", "https://www.nasdaq.com/articles/why-biotech-still-gets-hit-despite-promising-cancer-data-2017-11-13", "https://www.nasdaq.com/articles/why-five-prime-therapeutics-stock-rebound-today-2017-11-08", "https://www.nasdaq.com/articles/health-care-sector-update-11072017-selbmyofprxbmy-2017-11-07", "https://www.nasdaq.com/articles/noteworthy-tuesday-option-activity-hlf-mnk-fprx-2017-11-07", "https://www.nasdaq.com/articles/health-care-sector-update-11072017-tlgtmyofprxbmy-2017-11-07", "https://www.nasdaq.com/articles/stocks-showing-improving-market-leadership-five-prime-therapeutics-earns-83-rs-rating-2017", "https://www.nasdaq.com/articles/five-prime-therapeutics-inc.-fprx-jumps%3A-stock-rises-6.2-2017-10-13", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity-fprx-lulu-googl-2017-08-18", "https://www.nasdaq.com/articles/five-prime-therapeutics-becomes-oversold-fprx-2017-03-17", "https://www.nasdaq.com/articles/commit-buy-five-prime-therapeutics-35-earn-97-annualized-using-options-2017-02-01", "https://www.nasdaq.com/articles/bristol-myers-extends-deal-with-five-prime-therapeutics-2017-01-05", "https://www.nasdaq.com/articles/commit-buy-five-prime-therapeutics-40-earn-134-annualized-using-options-2016-11-01", "https://www.nasdaq.com/articles/stock-picks-quant-strategies-2016-10-04", "https://www.nasdaq.com/articles/stocks-showing-improving-market-leadership-five-prime-therapeutics-earns-83-rs-rating-2017", "https://www.nasdaq.com/articles/commit-purchase-five-prime-therapeutics-35-earn-97-annualized-using-options-2016-08-02", "https://www.nasdaq.com/articles/fprx-crosses-above-average-analyst-target-2016-07-19", "https://www.nasdaq.com/articles/bristol-myers-ucla-sign-immuno-oncology-collaboration-2015-12-15", "https://www.nasdaq.com/articles/noteworthy-etf-inflows-xbi-fprx-dyax-achn-2015-11-24", "https://www.nasdaq.com/articles/notable-etf-outflow-detected-xbi-fprx-dyax-ziop-2015-11-16", "https://www.nasdaq.com/articles/why-five-prime-therapeutics-rocketed-109-higher-october-2015-11-14", "https://www.nasdaq.com/articles/xbi-fprx-dyax-juno-etf-outflow-alert-2015-11-06", "https://www.nasdaq.com/articles/after-hours-earnings-report-march-10-2016-ulta-fnv-pay-htht-fnsr-vnet-fprx-mmi-iret-prsc", "https://www.nasdaq.com/articles/bristol-myers-bmy-daklinza-gets-nice-recommendation-2015-10-16", "https://www.nasdaq.com/articles/pre-market-most-active-oct-15-2015-nok-c-nflx-stx-vrx-bac-mtw-fprx-alu-tvix-tthi-xiv-2015", "https://www.nasdaq.com/articles/five-prime-therapeutics-and-bristol-myers-squibb-co-deepen-their-ties-2015-10-15", "https://www.nasdaq.com/articles/five-prime-therapeutics-stock-soars-over-60-news-deal-bristol-myers-squibb-2015-10-15", "https://www.nasdaq.com/articles/moving-average-crossover-alert%3A-five-prime-therapeutics-fprx-2015-09-02", "https://www.nasdaq.com/articles/3-top-small-cap-biotech-stocks-buy-right-now-2015-08-24", "https://www.nasdaq.com/articles/should-you-get-rid-of-five-prime-therapeutics-fprx-now-2015-08-13", "https://www.nasdaq.com/articles/lazy-way-invest-cancer-immunotherapy-2015-10-16", "https://www.nasdaq.com/articles/use-options-chance-buy-fprx-20-discount-2015-06-25", "https://www.nasdaq.com/articles/five-prime-therapeutics-fprx-jumps%3A-stock-rises-15.1-tale-of-the-tape-2015-05-28", "https://www.nasdaq.com/articles/after-hours-earnings-report-may-13-2015-csco-ntes-vips-ctrp-midd-jack-wx-jcp-cib-lxft-fprx", "https://www.nasdaq.com/articles/immuno-oncology-best-area-biotech-invest-right-now-2015-04-22", "https://www.nasdaq.com/articles/weakness-seen-in-five-prime-therapeutics-fprx-estimates%3A-should-you-stay-away-tale-of-the", "https://www.nasdaq.com/articles/after-hours-earnings-report-march-17-2015-orcl-adbe-nvgs-fprx-cpxx-aezs-bone-bcyp-2015-03", "https://www.nasdaq.com/articles/steven-cohens-newest-buys-additions-and-reductions-2015-03-04", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-amgen-exelixis-regeneron-five-prime-therapeutics-and", "https://www.nasdaq.com/articles/5-things-bristol-myers-squibb-cos-management-wants-you-know-2015-02-04", "https://www.nasdaq.com/articles/steven-cohen-buys-stake-company-looking-buyer-2015-01-29", "https://www.nasdaq.com/articles/tuesday-120-insider-buying-report-jpm-fprx-2015-01-20", "https://www.nasdaq.com/articles/could-common-medicine-cabinet-supplement-be-key-increased-survival-some-cancer-patie-2015", "https://www.nasdaq.com/articles/3-clinical-stage-biotech-stocks-should-be-your-watchlist-2015-2014-12-23", "https://www.nasdaq.com/articles/macrogenics-inks-deal-with-jj-for-blood-cancer-therapy-analyst-blog-2014-12-23", "https://www.nasdaq.com/articles/five-prime-therapeutics-up-on-deal-with-bristol-myers-analyst-blog-2014-11-26", "https://www.nasdaq.com/articles/has-pfizer-inc-finally-solved-its-immuno-oncology-problem-2015-02-18", "https://www.nasdaq.com/articles/monday-sector-leaders-music-electronics-stores-drugs-2014-11-24", "https://www.nasdaq.com/articles/five-prime-therapeutics-novel-target-licensed-by-glaxo-analyst-blog-2014-09-17", "https://www.nasdaq.com/articles/five-prime-therapeutics-fprx-jumps%3A-stock-adds-10.3-in-session-tale-of-the-tape-2014-08-12", "https://www.nasdaq.com/articles/bristol-myers-cytomx-therapeutics-join-forces-analyst-blog-2014-05-28", "https://www.nasdaq.com/articles/bristol-myers-samsung-biologics-extend-ties-analyst-blog-2014-04-23", "https://www.nasdaq.com/articles/should-five-prime-therapeutics-fprx-be-on-your-radar-now-tale-of-the-tape-2014-04-10", "https://www.nasdaq.com/articles/earnings-estimates-moving-higher-for-five-prime-fprx%3A-time-to-buy-tale-of-the-tape-2014-04", "https://www.nasdaq.com/articles/five-prime-therapeutics-inc.-fprx-in-focus%3A-stock-soars-31.4-tale-of-the-tape-2014-11-25", "https://www.nasdaq.com/articles/monday-sector-leaders-music-electronics-stores-drugs-2014-11-24", "https://www.nasdaq.com/articles/five-prime-therapeutics-novel-target-licensed-by-glaxo-analyst-blog-2014-09-17", "https://www.nasdaq.com/articles/five-prime-therapeutics-prices-ipo-13-within-range-2013-09-17", "https://www.nasdaq.com/articles/us-ipo-recap-benefitfocus-six-others-set-terms-calendar-rebuilds-2013-09-08", "https://www.nasdaq.com/articles/biotech-five-prime-therapeutics-sets-terms-52-million-ipo-2013-09-04", "https://www.nasdaq.com/articles/bristol-myers-deal-overshadows-q4-loss-at-five-prime-analyst-blog-2014-03-27"], "Content": []}